IBDEI0ZU ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,16167,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16167,1,3,0)
;;=3^Hypopituitarism
;;^UTILITY(U,$J,358.3,16167,1,4,0)
;;=4^E23.0
;;^UTILITY(U,$J,358.3,16167,2)
;;=^60685
;;^UTILITY(U,$J,358.3,16168,0)
;;=E27.1^^61^768^34
;;^UTILITY(U,$J,358.3,16168,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16168,1,3,0)
;;=3^Primary Adrenocortical Insufficiency
;;^UTILITY(U,$J,358.3,16168,1,4,0)
;;=4^E27.1
;;^UTILITY(U,$J,358.3,16168,2)
;;=^5002740
;;^UTILITY(U,$J,358.3,16169,0)
;;=E27.2^^61^768^1
;;^UTILITY(U,$J,358.3,16169,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16169,1,3,0)
;;=3^Addisonian Crisis
;;^UTILITY(U,$J,358.3,16169,1,4,0)
;;=4^E27.2
;;^UTILITY(U,$J,358.3,16169,2)
;;=^263725
;;^UTILITY(U,$J,358.3,16170,0)
;;=E27.3^^61^768^4
;;^UTILITY(U,$J,358.3,16170,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16170,1,3,0)
;;=3^Drug-induced Adrenocortical Insufficiency
;;^UTILITY(U,$J,358.3,16170,1,4,0)
;;=4^E27.3
;;^UTILITY(U,$J,358.3,16170,2)
;;=^5002741
;;^UTILITY(U,$J,358.3,16171,0)
;;=E29.1^^61^768^35
;;^UTILITY(U,$J,358.3,16171,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16171,1,3,0)
;;=3^Testicular Hypofunction
;;^UTILITY(U,$J,358.3,16171,1,4,0)
;;=4^E29.1
;;^UTILITY(U,$J,358.3,16171,2)
;;=^5002754
;;^UTILITY(U,$J,358.3,16172,0)
;;=E55.9^^61^768^42
;;^UTILITY(U,$J,358.3,16172,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16172,1,3,0)
;;=3^Vitamin D Deficiency,Unspec
;;^UTILITY(U,$J,358.3,16172,1,4,0)
;;=4^E55.9
;;^UTILITY(U,$J,358.3,16172,2)
;;=^5002799
;;^UTILITY(U,$J,358.3,16173,0)
;;=E66.01^^61^768^20
;;^UTILITY(U,$J,358.3,16173,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16173,1,3,0)
;;=3^Morbid Obesity
;;^UTILITY(U,$J,358.3,16173,1,4,0)
;;=4^E66.01
;;^UTILITY(U,$J,358.3,16173,2)
;;=^5002826
;;^UTILITY(U,$J,358.3,16174,0)
;;=E66.8^^61^768^24
;;^UTILITY(U,$J,358.3,16174,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16174,1,3,0)
;;=3^Obesity NEC
;;^UTILITY(U,$J,358.3,16174,1,4,0)
;;=4^E66.8
;;^UTILITY(U,$J,358.3,16174,2)
;;=^5002831
;;^UTILITY(U,$J,358.3,16175,0)
;;=E66.9^^61^768^25
;;^UTILITY(U,$J,358.3,16175,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16175,1,3,0)
;;=3^Obesity,Unspec
;;^UTILITY(U,$J,358.3,16175,1,4,0)
;;=4^E66.9
;;^UTILITY(U,$J,358.3,16175,2)
;;=^5002832
;;^UTILITY(U,$J,358.3,16176,0)
;;=E74.39^^61^768^16
;;^UTILITY(U,$J,358.3,16176,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16176,1,3,0)
;;=3^Intestinal Carbohydrate Absorption Disorder NEC
;;^UTILITY(U,$J,358.3,16176,1,4,0)
;;=4^E74.39
;;^UTILITY(U,$J,358.3,16176,2)
;;=^5002928
;;^UTILITY(U,$J,358.3,16177,0)
;;=E83.30^^61^768^28
;;^UTILITY(U,$J,358.3,16177,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16177,1,3,0)
;;=3^Phosphorus Metabolism Disorder,Unspec
;;^UTILITY(U,$J,358.3,16177,1,4,0)
;;=4^E83.30
;;^UTILITY(U,$J,358.3,16177,2)
;;=^5002997
;;^UTILITY(U,$J,358.3,16178,0)
;;=E83.51^^61^768^9
;;^UTILITY(U,$J,358.3,16178,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16178,1,3,0)
;;=3^Hypocalcemia
;;^UTILITY(U,$J,358.3,16178,1,4,0)
;;=4^E83.51
;;^UTILITY(U,$J,358.3,16178,2)
;;=^60542
;;^UTILITY(U,$J,358.3,16179,0)
;;=E83.52^^61^768^7
;;^UTILITY(U,$J,358.3,16179,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16179,1,3,0)
;;=3^Hypercalcemia
;;^UTILITY(U,$J,358.3,16179,1,4,0)
;;=4^E83.52
;;^UTILITY(U,$J,358.3,16179,2)
;;=^59932
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0ZU 3770 printed Sep 23, 2025@19:34:58 Page 2
IBDEI0ZU ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,16167,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,16167,1,3,0)
+4 ;;=3^Hypopituitarism
+5 ;;^UTILITY(U,$J,358.3,16167,1,4,0)
+6 ;;=4^E23.0
+7 ;;^UTILITY(U,$J,358.3,16167,2)
+8 ;;=^60685
+9 ;;^UTILITY(U,$J,358.3,16168,0)
+10 ;;=E27.1^^61^768^34
+11 ;;^UTILITY(U,$J,358.3,16168,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,16168,1,3,0)
+14 ;;=3^Primary Adrenocortical Insufficiency
+15 ;;^UTILITY(U,$J,358.3,16168,1,4,0)
+16 ;;=4^E27.1
+17 ;;^UTILITY(U,$J,358.3,16168,2)
+18 ;;=^5002740
+19 ;;^UTILITY(U,$J,358.3,16169,0)
+20 ;;=E27.2^^61^768^1
+21 ;;^UTILITY(U,$J,358.3,16169,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,16169,1,3,0)
+24 ;;=3^Addisonian Crisis
+25 ;;^UTILITY(U,$J,358.3,16169,1,4,0)
+26 ;;=4^E27.2
+27 ;;^UTILITY(U,$J,358.3,16169,2)
+28 ;;=^263725
+29 ;;^UTILITY(U,$J,358.3,16170,0)
+30 ;;=E27.3^^61^768^4
+31 ;;^UTILITY(U,$J,358.3,16170,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,16170,1,3,0)
+34 ;;=3^Drug-induced Adrenocortical Insufficiency
+35 ;;^UTILITY(U,$J,358.3,16170,1,4,0)
+36 ;;=4^E27.3
+37 ;;^UTILITY(U,$J,358.3,16170,2)
+38 ;;=^5002741
+39 ;;^UTILITY(U,$J,358.3,16171,0)
+40 ;;=E29.1^^61^768^35
+41 ;;^UTILITY(U,$J,358.3,16171,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,16171,1,3,0)
+44 ;;=3^Testicular Hypofunction
+45 ;;^UTILITY(U,$J,358.3,16171,1,4,0)
+46 ;;=4^E29.1
+47 ;;^UTILITY(U,$J,358.3,16171,2)
+48 ;;=^5002754
+49 ;;^UTILITY(U,$J,358.3,16172,0)
+50 ;;=E55.9^^61^768^42
+51 ;;^UTILITY(U,$J,358.3,16172,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,16172,1,3,0)
+54 ;;=3^Vitamin D Deficiency,Unspec
+55 ;;^UTILITY(U,$J,358.3,16172,1,4,0)
+56 ;;=4^E55.9
+57 ;;^UTILITY(U,$J,358.3,16172,2)
+58 ;;=^5002799
+59 ;;^UTILITY(U,$J,358.3,16173,0)
+60 ;;=E66.01^^61^768^20
+61 ;;^UTILITY(U,$J,358.3,16173,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,16173,1,3,0)
+64 ;;=3^Morbid Obesity
+65 ;;^UTILITY(U,$J,358.3,16173,1,4,0)
+66 ;;=4^E66.01
+67 ;;^UTILITY(U,$J,358.3,16173,2)
+68 ;;=^5002826
+69 ;;^UTILITY(U,$J,358.3,16174,0)
+70 ;;=E66.8^^61^768^24
+71 ;;^UTILITY(U,$J,358.3,16174,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,16174,1,3,0)
+74 ;;=3^Obesity NEC
+75 ;;^UTILITY(U,$J,358.3,16174,1,4,0)
+76 ;;=4^E66.8
+77 ;;^UTILITY(U,$J,358.3,16174,2)
+78 ;;=^5002831
+79 ;;^UTILITY(U,$J,358.3,16175,0)
+80 ;;=E66.9^^61^768^25
+81 ;;^UTILITY(U,$J,358.3,16175,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,16175,1,3,0)
+84 ;;=3^Obesity,Unspec
+85 ;;^UTILITY(U,$J,358.3,16175,1,4,0)
+86 ;;=4^E66.9
+87 ;;^UTILITY(U,$J,358.3,16175,2)
+88 ;;=^5002832
+89 ;;^UTILITY(U,$J,358.3,16176,0)
+90 ;;=E74.39^^61^768^16
+91 ;;^UTILITY(U,$J,358.3,16176,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,16176,1,3,0)
+94 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
+95 ;;^UTILITY(U,$J,358.3,16176,1,4,0)
+96 ;;=4^E74.39
+97 ;;^UTILITY(U,$J,358.3,16176,2)
+98 ;;=^5002928
+99 ;;^UTILITY(U,$J,358.3,16177,0)
+100 ;;=E83.30^^61^768^28
+101 ;;^UTILITY(U,$J,358.3,16177,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,16177,1,3,0)
+104 ;;=3^Phosphorus Metabolism Disorder,Unspec
+105 ;;^UTILITY(U,$J,358.3,16177,1,4,0)
+106 ;;=4^E83.30
+107 ;;^UTILITY(U,$J,358.3,16177,2)
+108 ;;=^5002997
+109 ;;^UTILITY(U,$J,358.3,16178,0)
+110 ;;=E83.51^^61^768^9
+111 ;;^UTILITY(U,$J,358.3,16178,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,16178,1,3,0)
+114 ;;=3^Hypocalcemia
+115 ;;^UTILITY(U,$J,358.3,16178,1,4,0)
+116 ;;=4^E83.51
+117 ;;^UTILITY(U,$J,358.3,16178,2)
+118 ;;=^60542
+119 ;;^UTILITY(U,$J,358.3,16179,0)
+120 ;;=E83.52^^61^768^7
+121 ;;^UTILITY(U,$J,358.3,16179,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,16179,1,3,0)
+124 ;;=3^Hypercalcemia
+125 ;;^UTILITY(U,$J,358.3,16179,1,4,0)
+126 ;;=4^E83.52
+127 ;;^UTILITY(U,$J,358.3,16179,2)
+128 ;;=^59932
